Sign in
ALDX Stock Price, Chart, Stats & News
Aldeyra The
Save
Aldeyra The (ALDX) does not currently pay a dividend.
105.56M
Market cap
–
Current P/E
–
Forward P/E
ALDX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | – |
ROA | -0.00% |
ROE | -0.00% |
D/E | 0.35x |
Interest coverage ratio | -18.51x |
ALDX valuation
P/E | – |
P/S | – |
P/B | 0.00x |
P/CF | 0.00x |
P/FCF | 0.00x |
P/OCF | 0.00x |
PEG | -0.14x |
EV multiple | 50.22x |
About
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication.
Similar securities
Based on sector and market capitalization
Report issue